Abstract
A N EW FO RM of immunotherapy has cmcrged that combines the bent.tits ol ccllu!ar ~md humorai immunotherapies. This thcrapy alters the specificity of T lymlphocytes, allowing them to recognize new MHC-unrcstricted targets, To do this, the T lymphocytes arc genetically modified to exlxess chimeric receptors that consist of ligandbinding domains dcrived from. antibodies or other rcceptors linked to sigmaling domains derived from the T cell receptor (TCR) or other activating recc.pmrs (.Fig 1). These modified receptors can both bind u~ a predetermined target, antigen as well as activate the genetically modified T cell. Receptorm{}dificd T cells have shown therapentic prontise in experimental models of a variety of pathologic processes, including cancer and infectious diseases, This review highlights the rationale for, design of, and recent preclinical and clinical trials with receptor-modified T lymphocytes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
